Nonlinear adaptive control of competitive release and chemotherapeutic resistance.
暂无分享,去创建一个
P K Newton | Y Ma | P. Newton | Yongqian Ma | Y. Ma
[1] Robert Gatenby,et al. Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer , 2015, Proceedings of the National Academy of Sciences.
[2] Paul Jaffe,et al. Orbital mechanics , 2017, IEEE Spectrum.
[3] Jeffrey West,et al. The prisoner's dilemma as a cancer model. , 2015, Convergent science physical oncology.
[4] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[5] Ville Mustonen,et al. The value of monitoring to control evolving populations , 2014, Proceedings of the National Academy of Sciences.
[6] R. Gatenby. A change of strategy in the war on cancer , 2009, Nature.
[7] M. Perry. The Chemotherapy Source Book , 1992, Annals of Internal Medicine.
[8] Troy Day,et al. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.
[9] P. Newton,et al. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies. , 2017, Cancer research.
[10] David Basanta,et al. Exploiting ecological principles to better understand cancer progression and treatment , 2013, Interface Focus.
[11] Alexander G. Fletcher,et al. Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance , 2015, PLoS Comput. Biol..
[12] Jacob G. Scott,et al. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs , 2017, Bulletin of Mathematical Biology.
[13] Ericka Stricklin-Parker,et al. Ann , 2005 .
[14] Josef Hofbauer,et al. Evolutionary Games and Population Dynamics , 1998 .
[15] Chen-Hsiang Yeang,et al. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.
[16] Paul K. Newton,et al. An Evolutionary Model of Tumor Cell Kinetics and the Emergence of Molecular Heterogeneity Driving Gompertzian Growth , 2015, SIAM Rev..
[17] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[18] Joel s. Brown,et al. The Evolution and Ecology of Resistance in Cancer Therapy. , 2018, Cold Spring Harbor perspectives in medicine.
[19] Shane D. Ross,et al. Connecting orbits and invariant manifolds in the spatial restricted three-body problem , 2004 .
[20] B. Levin,et al. The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.
[21] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[22] Frank Thuijsman,et al. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. , 2017, Journal of theoretical biology.
[23] Robert A Gatenby,et al. A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.
[24] Shane D. Ross,et al. Halo orbit mission correction maneuvers using optimal control , 2002, Autom..
[25] K. Pienta,et al. Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.
[26] J. Connell. The Influence of Interspecific Competition and Other Factors on the Distribution of the Barnacle Chthamalus Stellatus , 1961 .
[27] Quantifying Competitive Exclusion and Competitive Release in Ecological Communities: A Conceptual Framework and a Case Study , 2016, PloS one.
[28] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[29] Joel s. Brown,et al. Game theory as a conceptual framework for managing insect pests. , 2017, Current opinion in insect science.
[30] Shane D. Ross,et al. Multiple Gravity Assists, Capture, and Escape in the Restricted Three-Body Problem , 2007, SIAM J. Appl. Dyn. Syst..
[31] Piyush Grover,et al. Designing Trajectories in a Planet-Moon Environment Using the Controlled Keplerian Map , 2009 .
[32] David Basanta,et al. Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.
[33] F. Gould. The evolutionary potential of crop pests. , 1991 .
[34] Shane D. Ross,et al. Heteroclinic connections between periodic orbits and resonance transitions in celestial mechanics. , 2000, Chaos.
[35] Carlo C. Maley,et al. Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research , 2011, PloS one.
[36] C. Hauert,et al. Coevolutionary dynamics: from finite to infinite populations. , 2004, Physical review letters.
[37] R. Lewontin. The Units of Selection , 1970, The Structure and Confirmation of Evolutionary Theory.
[38] Joel s. Brown,et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.
[39] Camille Stephan-Otto Attolini,et al. Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.
[40] Sarah E Seton-Rogers,et al. Chemotherapy: Preventing competitive release , 2016, Nature Reviews Cancer.
[41] Michael C. Perry,et al. American Society of Clinical Oncology educational book , 2003 .
[42] R. Gillies,et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer , 2016, Science Translational Medicine.